Sentence: Sipuleucel-T , cabazitaxel , abiraterone , enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Sipuleucel-T', 'cabazitaxel', 'abiraterone', 'enzalutamide', 'radium-223'], 'is_context_needed': True}]